Pliant Therapeutics, Inc.
PLRX · United States
Share price · PLRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PLRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Nov 2026-5.8%
- 15 Oct 2026+10.0%
Nothing announced by PLRX that day or the session before.
- 14 Oct 2026-8.7%
Nothing announced by PLRX that day or the session before.
- 25 Sep 2026-5.3%
Nothing announced by PLRX that day or the session before.
- 16 Sep 2026-4.5%
Nothing announced by PLRX that day or the session before.
- 20 Jul 2026-7.0%
Nothing announced by PLRX that day or the session before.
- 14 Jul 2026-4.4%
- Day beforeDirector or principal officer change
- 16 Jun 2026+4.4%
Nothing announced by PLRX that day or the session before.
- 26 Mar 2026-6.1%
Nothing announced by PLRX that day or the session before.
- 12 Mar 2026+6.0%
Share of unusual movement by asset
For each asset, the share of PLRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Integrins αvβ8 and αvβ1Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $18M | $28M+ $115M short-term inv. | $24M-$17M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $17M | $26M+ $133M short-term inv. | $22M-$13M operating cash flow | report ↗ |
| 2026-Q1 | — | $14M | $24M+ $149M short-term inv. | $20M-$19M operating cash flow | report ↗ |
| 2025-Q3 | — | $18M | $95M+ $148M short-term inv. | $26M-$21M operating cash flow | report ↗ |
| 2025-Q2 | — | $32M | $88M+ $176M short-term inv. | $43M-$41M operating cash flow | report ↗ |
| 2025-Q1 | — | $43M | $93M+ $214M short-term inv. | $56M-$49M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $48M | $81M+ $325M short-term inv. | $58M-$32M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $46M | $82M+ $356M short-term inv. | $56M-$45M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $37M | $116M+ $368M short-term inv. | $47M-$30M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $32M | $58M+ $466M short-term inv. | $41M-$36M operating cash flow | report ↗ |
| 2023-Q2 | $0.3M | $33M | $55M+ $500M short-term inv. | $41M-$25M operating cash flow | report ↗ |
| 2023-Q1 | $1.3M | $29M | $103M+ $475M short-term inv. | $38M-$30M operating cash flow | report ↗ |
| 2022-Q3 | $1.5M | $25M | $45M+ $316M short-term inv. | $31M-$19M operating cash flow | report ↗ |
| 2022-Q2 | $5.0M | $26M | $25M+ $139M short-term inv. | $30M-$24M operating cash flow | report ↗ |
| 2022-Q1 | $1.3M | $21M | $33M+ $146M short-term inv. | $28M-$21M operating cash flow | report ↗ |
| 2021-Q3 | $1.6M | $21M | $45M+ $176M short-term inv. | $27M-$23M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $109M | $47M+ $146M short-term inv. | $37M-$128M operating cash flow | report ↗ |
For fiscal year 2025, Pliant Therapeutics reported revenue of $0M (prior year: $0M), R&D spend of $109.16M, down 35.5% YoY, and cash and equivalents of $46.93M. The company reported a net loss of $149.34M and a quarterly net burn of $149.34M.
Pliant announced positive Phase 1 dose-escalation data for its lead candidate PLN-101095 in patients with immune-checkpoint-inhibitor-resistant solid tumors, including responses across the three highest dose cohorts, and plans to initiate a Phase 1b indication expansion trial in 2026. The company discontinued development of bexotegrast in IPF following a data review and is evaluating the path forward for PSC after regulatory discussions, while continuing to advance its integrin-binding molecule platform for targeted drug delivery.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $169M | $73M+ $285M short-term inv. | $53M-$156M operating cash flow | report ↗ |
| 2023-FY | $1.6M | $128M | $65M+ $431M short-term inv. | $40M-$116M operating cash flow | report ↗ |
| 2022-FY | $9.7M | $97M | $34M+ $298M short-term inv. | $31M-$95M operating cash flow | report ↗ |
| 2021-FY | $7.6M | $78M | $52M+ $149M short-term inv. | $24M-$75M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($164K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Raben David · Chief Medical Officer | Award / grant (derivative) | 575,000 | — | — | Form 4 |
| 2026-07-09 | Borellini Flavia · director | Award / grant (derivative) | 60,000 | — | — | Form 4 |
| 2026-07-09 | Iannone Robert · director | Award / grant (derivative) | 60,000 | — | — | Form 4 |
| 2026-06-11 | Cline Darren S · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-11 | Huh Hoyoung · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-11 | Curnutte John T · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-11 | Krognes Steve E. · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-11 | MCCOURT Thomas A · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 91 reporting institutions held 49.7M shares ($58.1M, 80.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 6,143,132 | $7.7M |
| 2 | CITADEL ADVISORS LLC | 3,226,599 | $4.1M |
| 3 | Blue Owl Capital Holdings LP | 2,969,199 | $3.7M |
| 4 | ADAR1 Capital Management, LLC | 2,585,126 | $3.3M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,343,101 | $3.0M |
| 6 | TWO SIGMA INVESTMENTS, LP | 2,253,138 | $2.8M |
| 7 | Monaco Asset Management SAM | 1,938,747 | $2.4M |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 1,852,842 | $2.3M |
| 9 | Prosight Management, LP | 1,667,600 | $2.1M |
| 10 | Woodline Partners LP | 1,666,830 | $2.1M |
| 11 | BML Capital Management, LLC | 1,546,137 | $1.9M |
| 12 | Peapod Lane Capital LLC | 1,288,578 | $1.6M |
| 13 | MILLENNIUM MANAGEMENT LLC | 1,180,518 | $1.5M |
| 14 | BlackRock, Inc. | 1,096,430 | $1.4M |
| 15 | UBS Group AG | 1,057,954 | $1.3M |